

Prof. ŞUAYİB YALÇIN

Personal Information

Office Phone: [+90 312 467 3030](tel:+903124673030)

Fax Phone: [+90 312 467 1313](tel:+903124671313)

Email: syalcin@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/syalcin>

International Researcher IDs

ORCID: 0000-0001-7850-6798

Yoksis Researcher ID: 169171

Education Information

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, Turkey 1983 - 1989

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic and Administrative Experience

Hacettepe Üniversitesi, Tıp Fakültesi, 2008 - 2012

Hacettepe Üniversitesi, Kanser Enstitüsü, Klinik Onkoloji Anabilim Dalı, 2009 - 2011

Hacettepe Üniversitesi, Hacettepe Tıp Fakültesi, 2002 - 2008

Advising Theses

YALÇIN Ş., Mide kanseri tanısı konmuş yetişkin bireylerin yaşam tarzı ve beslenme alışkanlıklarının değerlendirilmesi, Postgraduate, E.YASSIBAŞ(Student), 2009

Published journal articles indexed by SCI, SSCI, and AHCI

- I. Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial**
YILMAZ F., YAŞAR S., Mandel N. M., Kacan T., Ozdemir M., DOĞU G. G., Sengul N., Meydan N., Basal F. B., KUBİLAY TOLUNAY P., et al.
TARGETED ONCOLOGY, 2024 (SCI-Expanded)
- II. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors**
KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., AKSOY S., ERMAN M., YALÇIN Ş.
SUPPORTIVE CARE IN CANCER, no.7, 2024 (SCI-Expanded)
- III. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study**

KUTLU Y., Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., Senocak Tasci E., BAŞ O., Dane F., SAKİN A., et al. *CANCERS*, no.12, 2024 (SCI-Expanded)

- IV. **Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study**
ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., Uslu R., Mandel N. M., YALÇIN Ş., Teomete M., et al. *JAPANESE JOURNAL OF CLINICAL ONCOLOGY*, no.5, pp.562-568, 2024 (SCI-Expanded)
- V. **Long-term results of liver thermal ablation in patients with hepatocellular carcinoma and colorectal cancer liver metastasis regarding spatial features and tumor-specific variables**
AKHAN O., ERDEMİR A. G., KARAHAN S., ÜNAL E., ÇİFTÇİ T. T., AKINCI D., YALÇIN Ş.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, no.3, pp.183-192, 2024 (SCI-Expanded)
- VI. **The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review**
GÜVEN D. C., KAVGACI G., ERUL E., Syed M. P., Magge T., Saeed A., YALÇIN Ş., Sahin I. H.
ONCOLOGIST, 2024 (SCI-Expanded)
- VII. **A Post-International Gastrointestinal Cancers Conference (IGICC) Position Statements '**
YALÇIN Ş., Lacin S., Kaseb A. O., PEYNİRCİOĞLU B., Cantasdemir M., ÇİL B. E., HÜR MÜZ P., Dorul A. B., BOZKURT M. F., Abali H., et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA, pp.953-974, 2024 (SCI-Expanded)
- VIII. **The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study**
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., Chalabiyev E., AKYILDIZ A., KÖKSAL B., ŞAHİN Y. B., et al.
INTEGRATIVE CANCER THERAPIES, vol.23, 2024 (SCI-Expanded)
- IX. **Sirolimus experience in adult patients with vascular malformations**
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., Chalabiyev E., TÜRKER F. A., DİZDAR Ö., YALÇIN Ş., et al.
Vascular, 2024 (SCI-Expanded)
- X. **Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy**
Sahin T. K., ÖZBAY Y., ALTUNBULAK A. Y., ALTUNBULAK H. İ., ONUR M. R., Ceylan F., GÜVEN D. C., YALÇIN Ş., DİZDAR Ö.
International Journal of Clinical Oncology, 2024 (SCI-Expanded)
- XI. **KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer**
André T., Pietrantonio F., Avallone A., Gumus M., Wyrwicz L., Kim J. G., YALÇIN Ş., Kwiatkowski M., Lonardi S., Zolnierek J., et al.
Future Oncology, vol.19, no.37, pp.2445-2452, 2023 (SCI-Expanded)
- XII. **A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology**
YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.
Irish Journal of Medical Science, vol.192, no.6, pp.2631-2634, 2023 (SCI-Expanded)
- XIII. **The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey**
AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., YILDIZ İ., Iriagac Y., Turhal S., Akbas S., et al.
Medicine, vol.102, no.45, 2023 (SCI-Expanded)
- XIV. **Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia**
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., GÜNER G., GÜVEN D. C., ARIK Z., KERTMEN N., et al.
Current Oncology, vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded)
- XV. **A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient**

with BRCA2 mutant metastatic pancreatic cancer

YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., YALÇIN Ş.
Anti-cancer drugs, vol.34, no.10, pp.1190-1192, 2023 (SCI-Expanded)

- XVI. **Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group**
Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., YALÇIN Ş., Çoban E., EVRENSEL T., Kalkan Z., et al.
The oncologist, vol.28, no.10, pp.875-884, 2023 (SCI-Expanded)
- XVII. **The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study**
GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., AKSOY S., ERMAN M., YALÇIN Ş., ÜRÜN Y., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded)
- XVIII. **The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors**
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., YILDIRIM H. Ç., Chalabiyev E., Cebroyilov C., YILDIRIM T., et al.
Anti-Cancer Drugs, vol.34, no.6, pp.783-790, 2023 (SCI-Expanded)
- XIX. **Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort**
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., Chalabiyev E., KUŞ F., YALÇIN Ş., AKSOY S.
Medicine (United States), vol.102, no.18, 2023 (SCI-Expanded)
- XX. **Clinical Characteristics and Outcomes of Cancer Cases Among Syrian Refugees From Southern Turkey**
Kutluk T., ŞAHİN B., Kirazli M., Ahmed F., Aydin S., Yesil Çinkir H., SEZGİN G., BAYRAM İ., Ebinç S., Isikdogan A., et al.
JAMA network open, vol.6, no.5, 2023 (SCI-Expanded)
- XXI. **Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer**
Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., Turker A., Hamaloglu E., KARAKOÇ D., Isik A., et al.
Clinics and Research in Hepatology and Gastroenterology, vol.47, no.3, 2023 (SCI-Expanded)
- XXII. **Oncology-Led Early Identification of Nutritional Risk: A Pragmatic, Evidence-Based Protocol (PRONTO)**
Muscaritoli M., Bar-Sela G., Battisti N. M. L., Belev B., Contreras-Martínez J., Cortesi E., de Brito-Ashurst I., Prado C. M., Ravasco P., YALÇIN Ş.
Cancers, vol.15, no.2, 2023 (SCI-Expanded)
- XXIII. **Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study**
BAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., Tataroglu ozyukseler D., Ayhan M., Sendur M. A., Dogan M., et al.
JOURNAL OF CHEMOTHERAPY, vol.35, no.2, pp.142-149, 2023 (SCI-Expanded)
- XXIV. **Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations**
KAHRAMAN S., Bardakci M., Aykan M. B., YAŞAR S., Erol C., Hizal M., Akinci M. B., Kos F. T., Kos T., Dede D. S., et al.
Journal of cancer research and therapeutics, vol.19, no.2, pp.347-354, 2023 (SCI-Expanded)
- XXV. **Emerging treatment strategies in hepatobiliary cancer**
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., AKYILDIZ A., AKTAŞ B. Y., YALÇIN Ş., DİZDAR Ö.
Expert Review of Anticancer Therapy, vol.23, no.3, pp.243-256, 2023 (SCI-Expanded)
- XXVI. **The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis**

- GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., YALÇIN Ş.
Frontiers in Molecular Biosciences, vol.9, 2022 (SCI-Expanded)
- XXVII. **Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study**
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., Celebi A., DURSUN B., Acar O., KAHRAMAN S., et al.
BREAST, vol.66, pp.85-88, 2022 (SCI-Expanded)
- XXVIII. **Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine**
Carloni R., Rizzo A., Ricci A. D., Di Federico A., De Luca R., GÜVEN D. C., YALÇIN Ş., Brandi G.
TRANSLATIONAL ONCOLOGY, vol.25, 2022 (SCI-Expanded)
- XXIX. **Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKSOY S., ERMAN M., Kilickap S., YALÇIN Ş.
JOURNAL OF CLINICAL MEDICINE, vol.11, no.17, 2022 (SCI-Expanded)
- XXX. **Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey**
ÖZET A., DANE F., Aykan N. F., YALÇIN Ş., EVRENSEL T., ÖZKAN M., Karabulut B., Ormeci M. N., Atasev O., Vidot L., et al.
FUTURE ONCOLOGY, vol.18, no.29, pp.3267-3276, 2022 (SCI-Expanded)
- XXXI. **The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy**
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., AKTEPE O. H., ERMAN M., KILIÇKAP S., AKSOY S., et al.
JOURNAL OF CLINICAL MEDICINE, vol.11, no.15, 2022 (SCI-Expanded)
- XXXII. **Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis**
Rizzo A., Carloni R., Ricci A. D., Di Federico A., GÜVEN D. C., YALÇIN Ş., Brandi G.
JOURNAL OF PERSONALIZED MEDICINE, vol.12, no.8, 2022 (SCI-Expanded)
- XXXIII. **The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy**
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., ERMAN M., KILIÇKAP S., YALÇIN Ş.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.4, pp.785-793, 2022 (SCI-Expanded)
- XXXIV. **Examining guidelines and new evidence in oncology nutrition: a position paper on gaps and opportunities in multimodal approaches to improve patient care**
Prado C. M., Laviano A., Gillis C., Sung A. D., Gardner M., YALÇIN Ş., Dixon S., Newman S. M., Bastasch M. D., Sauer A. C., et al.
SUPPORTIVE CARE IN CANCER, vol.30, no.4, pp.3073-3083, 2022 (SCI-Expanded)
- XXXV. **Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study**
Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., Tunc S., Ozyurt N., Ozdemir F., Sendur M. A. N., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.4, 2022 (SCI-Expanded)
- XXXVI. **Classification of early-stage colon cancer with Immunoscore (R): clinical evidence and case studies**
YALÇIN Ş., Philip P. A., Athanasiadis I., Bazarbashi S., Shamseddine A.
FUTURE ONCOLOGY, vol.18, pp.613-623, 2022 (SCI-Expanded)
- XXXVII. **Surgical, pathological and clinical features of advanced colorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data**
Karadurmus N., Yildirim E., Yalcin S., Gumus M., Bilir C., Cubukcu E., Simsek E. T., Arslan C., Dane F., Celik S., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.4, 2022 (SCI-Expanded)
- XXXVIII. **Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment**

GÜRLER F., İlhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., Yildiz F., ARIK Z., Oksuzoglu B., YALÇIN Ş., et al.

ANTI-CANCER DRUGS, vol.33, no.1, 2022 (SCI-Expanded)

XXXIX. **Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients**

Tsaousis G. N., Papadopoulou E., Agiannitopoulos K., Pepe G., Tsoulos N., Boukovinas I., Floros T., Iosifidou R., Katopodi O., Koumariou A., et al.

CANCER GENOMICS & PROTEOMICS, vol.19, no.1, pp.60-78, 2022 (SCI-Expanded)

XL. **Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)**

Erol C., Sakin A., Başoglu T., Özden E., ÇABUK D., Doğan M., Öksüzöğlü B., YILDIRIM H. Ç., Öner İ., Karakurt Eryilmaz M., et al.

Turkish Journal of Medical Sciences, vol.52, no.4, pp.1022-1032, 2022 (SCI-Expanded)

XLI. **Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma**

Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., İnci B. K., ARIK Z., YALÇIN Ş., ÖZDEMİR N., ÖZET A., YAZICI O. TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1559-1568, 2022 (SCI-Expanded)

XLII. **Excessive screen time and lower psychosocial well-being among preschool children**

Tezol O., Yildiz D., YALÇIN Ş., Oflu A., Erat Nergiz M., Caylan N., Cıcek S., FOTO ÖZDEMİR D.

Archives de Pediatrie, vol.29, pp.61-66, 2022 (SCI-Expanded)

XLIII. **Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats**

AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., ÖZERCAN İ. H., DİZDAR Ö., YALÇIN Ş. TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.12, pp.1049-1056, 2021 (SCI-Expanded)

XLIV. **A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer**

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.168, 2021 (SCI-Expanded)

XLV. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., İncesu F. G. G., TAHILLIOĞLU Y., ÜÇGÜL E., AKSUN M. S., GÜRBÜZ S. Ç., AKTEPE O. H., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)

XLVI. **Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors**

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., ŞAHİN T. K., AKSUN M. S., DİZDAR Ö., AKSOY S., et al.

BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded)

XLVII. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.

SUPPORTIVE CARE IN CANCER, vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded)

XLVIII. **Neoadjuvant capecitabine in rectal cancer chemoradiotherapy: too early to ring the alarms**

GÜVEN D. C., YALÇIN Ş.

INTERNAL MEDICINE JOURNAL, vol.51, no.8, pp.1365-1366, 2021 (SCI-Expanded)

XLIX. **A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study**

Abali H., YALÇIN Ş., Onal H. C., Dane F., Oksuzoglu B., ÖZDEMİR N., Mertsoylu H., ARTAÇ M., Camci C., KARABULUT B., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.44, no.7, pp.301-307, 2021 (SCI-Expanded)

- L. **A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience**
Pauli C., Bochtler T., Mileskin L., Baciarello G., Losa F., Ross J. S., Pentheroudakis G., Zarkavelis G., YALÇIN Ş., ÖZGÜROĞLU M., et al.
ONCOLOGIST, vol.26, no.5, 2021 (SCI-Expanded)
- LI. **Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.**
Kefeli U., Arslan C., Yildirim M. E., Isikdogan A., Karadurmus N., Karabulut B., Cubukcu E., Cicin I., Yalcin S., Turk H. M., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- LII. **THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY**
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., YILDIRIM T., DİZDAR Ö., AKSOY S., KILIÇKAP S., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, 2021 (SCI-Expanded)
- LIII. **The relation between inflammation-based parameters and survival in metastatic pancreatic cancer**
Turker S., Cilbir E., GÜVEN D. C., Karacin C., YALÇIN Ş.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.17, no.2, pp.510-515, 2021 (SCI-Expanded)
- LIV. **Neoadjuvant Radiotherapy in Rectal Cancer: A Single Center Experience**
HÜR MÜZ P., TILKİ B., CENGİZ M., YILDIZ F., ÖZYİĞİT G., EROL T., KONAN A., Zorlu F., YALÇIN Ş., Akyol F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.3, pp.178-184, 2021 (SCI-Expanded)
- LV. **Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer**
KAHRAMAN S., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.14, pp.4149-4162, 2021 (SCI-Expanded)
- LVI. **V600E and Non-V600E BRAF Mutations in Colorectal Cancer: Clinicopathologic Correlations in a Single Institution**
ŞİMŞEK C., LAÇIN Ş., Ece E., YALÇIN Ş.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.1, pp.43-49, 2021 (SCI-Expanded)
- LVII. **The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer**
Lacin S., YALÇIN Ş.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, vol.19, 2020 (SCI-Expanded)
- LVIII. **Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients**
Abdel-Wahab R., Hassan M. M., George B., Pestana R. C., Xiao L., Lacin S., YALÇIN Ş., Shalaby A. S., Al-Shamsi H. O., Raghav K., et al.
ONCOLOGY, vol.98, no.12, pp.836-846, 2020 (SCI-Expanded)
- LIX. **Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience**
AKIN TELLİ T., Esin E., YALÇIN Ş.
BALKAN MEDICAL JOURNAL, vol.37, no.5, pp.281-286, 2020 (SCI-Expanded)
- LX. **Anti-prostate cancer activity of a nanof ormulation of the spleen tyrosine kinase (SYK) inhibitor C61**
ŞAHİN T. K., AKTEPE O. H., Uckun F. M., YALÇIN Ş.
ANTI-CANCER DRUGS, vol.31, no.6, pp.609-616, 2020 (SCI-Expanded)
- LXI. **Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS**
Tabernero J., Alsina M., Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., Ghidini M., Faustino C., et al.
GASTRIC CANCER, vol.23, no.4, pp.689-698, 2020 (SCI-Expanded)
- LXII. **Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer**

in Turkey: the single-arm, open-label REGARD study

Dane F, Ozgurdal K, YALÇIN Ş, BENEKLİ M., Aykan N. F., YÜCEL İ., ÖZKAN M., EVRENSEL T., Sevinc A., COŞKUN H. Ş., et al.

BMJ OPEN, vol.10, no.3, 2020 (SCI-Expanded)

- LXIII. **Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study**
YALÇIN Ş, DANE F, Oksuzoglu B, Ozdemir N. Y., Isikdogan A, ÖZKAN M., Demirag G. G., COŞKUN H. Ş., KARABULUT B., Evrensel T., et al.
BMC CANCER, vol.20, no.1, 2020 (SCI-Expanded)
- LXIV. **Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience**
Karakas Y., Lacin S., KURTULAN O., Esin E., Sunar V., SÖKMENSÜER C., KILIÇKAP S., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.2, pp.91-98, 2020 (SCI-Expanded)
- LXV. **Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study**
Lacin S., YALÇIN Ş., Karakas Y., Hassan M. M., Amin H., Mohamed Y. I., Rashid A., Morris J. S., Xiao L., Qayyum A., et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA, vol.7, pp.143-153, 2020 (SCI-Expanded)
- LXVI. **The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer**
Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M., Xiao L., Kaseb A. O., YALÇIN Ş.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, no.2, pp.94-102, 2020 (SCI-Expanded)
- LXVII. **Nutritional Aspect of Cancer Care in Medical Oncology Patients**
YALÇIN Ş., GÜMÜŞ M., Oksuzoglu B., ÖZDEMİR F., EVRENSEL T., Sarioglu A. A., ŞAHİN B., Mandel N. M., GÖKER E.
CLINICAL THERAPEUTICS, vol.41, no.11, pp.2382-2396, 2019 (SCI-Expanded)
- LXVIII. **Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)**
Riechelmann R. P., Srimuninnimit V., Bordonaro R., Kavan P., Di Bartolomeo M., Maiello E., ÇİÇİN İ., Garcia-Alfonso P., Chau I., Fedyanin M. Y., et al.
CLINICAL COLORECTAL CANCER, vol.18, no.3, pp.183-194, 2019 (SCI-Expanded)
- LXIX. **Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases**
Ates O., YALÇIN Ş.
INDIAN JOURNAL OF CANCER, vol.56, no.2, pp.176-179, 2019 (SCI-Expanded)
- LXX. **The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy**
ŞAHİN T., DİZDAR Ö., Ozdemir N., Zengin N., Ates O., Oksuzoglu B., ŞENDUR M. A. N., Bilgin B., DEMİR M., BOZBULUT U. B., et al.
ANTI-CANCER DRUGS, vol.30, no.3, pp.289-294, 2019 (SCI-Expanded)
- LXXI. **Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience**
ŞİMŞEK C., Esin E., YALÇIN Ş.
JOURNAL OF ONCOLOGY, vol.2019, 2019 (SCI-Expanded)
- LXXII. **First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study**
Beypinar I., ARAZ M., UYSAL M., YALÇIN Ş.
JOURNAL OF BUON, vol.24, no.1, pp.68-76, 2019 (SCI-Expanded)
- LXXIII. **Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma**
YALÇIN Ş., Lacin S.
CANCER MANAGEMENT AND RESEARCH, vol.11, pp.7779-7785, 2019 (SCI-Expanded)
- LXXIV. **Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial**
Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., Alsina M., Ghidini M., Faustino C., Gorbunova

V., et al.

LANCET ONCOLOGY, vol.19, no.11, pp.1437-1448, 2018 (SCI-Expanded)

- LXXV. **Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial**
YALÇIN Ş., ÖZGÜROĞLU M., shitara K., bang y. j., bartolomeo m. d., mandala m., ryu m.
Lancet, vol.392, no.10142, pp.123-133, 2018 (SCI-Expanded)
- LXXVI. **Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey**
ESİN E., YILDIZ F., Lacin S., KARAKAS Y., GÜLTEKİN M., DİZDAR Ö., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.4, pp.411-418, 2018 (SCI-Expanded)
- LXXVII. **A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity**
Esin E., Telli T. A., YÜCE D., YALÇIN Ş.
TUMORI J, vol.104, no.3, pp.157-164, 2018 (SCI-Expanded)
- LXXVIII. **Clinicopathologic features of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): A single-center experience.**
Telli T. A., Esin E., Yalcin S.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- LXXIX. **Recent advances in the management of pancreatic adenocarcinoma**
Karakas Y., LAÇİN Ş., YALÇIN Ş.
EXPERT REVIEW OF ANTICANCER THERAPY, vol.18, no.1, pp.51-62, 2018 (SCI-Expanded)
- LXXX. **A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study**
YALÇIN Ş., Yildiz R., Dane F., Karaoglu A., Oksuzoglu B., ÖZYILKAN Ö., Sevinc A., ÖZDEMİR F., TURNA Z. H., Uslu R., et al.
ONCOTARGETS AND THERAPY, vol.11, pp.1223-1228, 2018 (SCI-Expanded)
- LXXXI. **Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up**
YALÇIN Ş., BAYRAM F., ERDAMAR ÇETİN A. S., Kucuk O., ORUÇ N., Coker A.
ARCHIVES OF MEDICAL SCIENCE, vol.13, no.2, pp.271-282, 2017 (SCI-Expanded)
- LXXXII. **Renal cell cancer: overview of the current therapeutic landscape**
ERMAN M., Benekli M., Basaran M., BAVBEK S., Buyukberber S., Coskun U., DEMİR G., KARABULUT B., OKSUZOGLU B., ÖZKAN M., et al.
EXPERT REVIEW OF ANTICANCER THERAPY, vol.16, no.9, pp.955-968, 2016 (SCI-Expanded)
- LXXXIII. **Maternal risk factors associated with lead, mercury and cadmium levels in umbilical cord blood, breast milk and newborn hair**
Dursun A., YURDAKÖK K., YALÇIN Ş., Tekinalp G., Aykut O., Orhan G., Morgil G. K.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, vol.29, no.6, pp.954-961, 2016 (SCI-Expanded)
- LXXXIV. **A case of acanthosis nigricans as a paraneoplastic syndrome with squamous cell lung cancer**
Karakas Y., Esin E., LAÇİN Ş., Ceyhan K., HEPER A., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.9, pp.4815-4820, 2016 (SCI-Expanded)
- LXXXV. **Maintenance strategy in metastatic colorectal cancer: A systematic review**
Esin E., YALÇIN Ş.
CANCER TREATMENT REVIEWS, vol.42, pp.82-90, 2016 (SCI-Expanded)
- LXXXVI. **Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors**
Yildiz Y., SÖKMENSÜER C., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.9, pp.5809-5817, 2016 (SCI-Expanded)
- LXXXVII. **Effects of infrared treatment on tocopherols, total phenolics and antioxidant activity of soybean samples**
YALÇIN Ş., BAŞMAN A.
QUALITY ASSURANCE AND SAFETY OF CROPS & FOODS, vol.8, no.2, pp.273-281, 2016 (SCI-Expanded)

- LXXXVIII. **Clinical Outcomes of Patients With Advanced Gastrointestinal Stromal Tumors: Safety and Efficacy in a Worldwide Treatment-Use Trial of Sunitinib**
Reichardt P., Kang Y., Rutkowski P., Schuette J., Rosen L. S., Seddon B., YALÇIN Ş., Gelderblom H., Williams C. C., Fumagalli E., et al.
CANCER, vol.121, no.9, pp.1405-1413, 2015 (SCI-Expanded)
- LXXXIX. **Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)**
Aykan N. F., YALÇIN Ş., Turhal N. S., Ozdogan M., Demir G., ÖZKAN M., YAREN A., Camci C., AKBULUT H., Artac M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.26, no.2, pp.145-153, 2015 (SCI-Expanded)
- XC. **Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population**
BENEKLİ M., YALÇIN Ş., ÖZKAN M., ELKIRAN E. T., Sevinc A., ÇABUK D., COŞKUN H. Ş., Oksuzoglu B., Bayar B., Akbulat A., et al.
ONCOTARGETS AND THERAPY, vol.8, pp.1-5, 2015 (SCI-Expanded)
- XCI. **Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen**
LAÇİN Ş., Esin E., Karakas Y., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.8, pp.1039-1042, 2015 (SCI-Expanded)
- XCII. **EVALUATION OF QUALITY OF LIFE AND ANXIETY AND DEPRESION LEVELS IN PATIENTS RECEIVING CHEMOTHERAPY FOR COLORECTAL CANCER: IMPACT OF PATIENT EDUCATION BEFORE TREATMENT INITIATION**
Yalcin S., Polat U., Arpacı A., Demir S., Erdal S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol.10, pp.181, 2014 (SCI-Expanded)
- XCIII. **Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study**
Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., Oguz D., Bostanci B., Yalcin B., Zengin N.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.74, no.6, pp.1139-1147, 2014 (SCI-Expanded)
- XCIV. **Transient hypertrophic pyloric stenosis due to prostoglandin infusion**
Sayer T., YALÇIN Ş., Bozkaya D., YIĞİT Ş., TANYEL F. C.
JOURNAL OF PERINATOLOGY, vol.34, no.10, pp.800-801, 2014 (SCI-Expanded)
- XCV. **End-of-study results of Turkish gastric cancer patients from the global REGATE study**
YALÇIN Ş., Gumus M., KILIÇKAP S., Alkis N., Ilhan M., Oksuzoglu B., Orhan B., Unsal M., TEKİN S. B., Yalcin B., et al.
JOURNAL OF BUON, vol.19, no.2, pp.377-387, 2014 (SCI-Expanded)
- XCVI. **Ultrasound Scanning of the Proximal Plexus in Diabetic Cervical Radiculoplexopathy**
Yalcin S., Kara M., Tiftik T., Erden E., Ersoz M., Ozcakar L.
WEST INDIAN MEDICAL JOURNAL, vol.63, no.2, pp.208-209, 2014 (SCI-Expanded)
- XCVII. **Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement**
YALÇIN Ş., Trad D., Kader Y. A., Halawani H., Demir O. G., Mall R., Meshcheryakov A., Nasr F., Nosworthy A., Osinsky D., et al.
FUTURE ONCOLOGY, vol.10, no.16, pp.2643-2657, 2014 (SCI-Expanded)
- XCVIII. **Analysis of Resected Gastric Cancer in Turkish Population**
Demir G., Unsal D., Zengin N., ER Ö., Dane F., YALÇIN Ş.
HEPATO-GASTROENTEROLOGY, vol.61, no.129, pp.259-266, 2014 (SCI-Expanded)
- XCIX. **Neuropathic cancer pain: What we are dealing with? How to manage it?**
Esin E., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.7, pp.599-618, 2014 (SCI-Expanded)
- C. **Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy**
OZCAN M. F., Dizdar O., DINCER N., BALCI S., Guler G., GOK B., PEKTAS G., SEKER M. M., AKSOY S., Arslan C., et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.31, no.8, pp.1709-1715, 2013 (SCI-Expanded)

- CI. **Increasing performance of a hospital-based cancer registry: Hacettepe University hospitals experience**
Kutluk T., HAYRAN K. M., Kilickap S., Yuce D., Celik I., Erman M., Yalcin S.
JOURNAL OF BUON, vol.18, no.4, pp.1088-1096, 2013 (SCI-Expanded)
- CII. **Breast cancer in octogenarian women: clinical characteristics and outcome**
Kuzan T. Y., Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., Rahatli S., Dede D. S., et al.
JOURNAL OF BUON, vol.18, no.2, pp.328-334, 2013 (SCI-Expanded)
- CIII. **A review of the use of somatostatin analogs in oncology**
Keskin O., YALÇIN Ş.
ONCOTARGETS AND THERAPY, vol.6, pp.471-483, 2013 (SCI-Expanded)
- CIV. **Transarterial Chemo and Radioembolization (Yttrium90) of Hepatic Metastasis of Neuroendocrine Tumors: Single Center Experience**
Ozkan F., PEYNİRCİOĞLU B., ÇİL B. E., Yurttutan N., YALÇIN Ş., BALKANCI F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.1, pp.20-27, 2013 (SCI-Expanded)
- CV. **Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III 'Stop and Go' Study Results - A Turkish Oncology Group Trial**
YALÇIN Ş., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., ŞENCAN O., Kilickap S., et al.
ONCOLOGY, vol.85, no.6, pp.328-335, 2013 (SCI-Expanded)
- CVI. **Salmonella gastroenteritis in children (clinical characteristics and antibiotic susceptibility): comparison of the years 1995-2001 and 2002-2008**
Ince O. T., YALÇIN Ş., YURDAKÖK K., ÖZMERT E. N., Aydın A., Baris Z., Gur D.
TURKISH JOURNAL OF PEDIATRICS, vol.54, no.5, pp.465-473, 2012 (SCI-Expanded)
- CVII. **Screening Colonoscopy Participation in Turkish Colorectal Cancer Patients and their First Degree Relatives**
KILIÇKAP S., ARSLAN Ç., Rama D., YALÇIN Ş.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.6, pp.2829-2832, 2012 (SCI-Expanded)
- CVIII. **Utility of "Over D1" or D1 Nodal Dissections in Predicting Outcome of Patients with Gastric Adenocarcinoma Treated with Postoperative Concurrent Chemoradiotherapy**
SELEK U., Zorlu F., ÖZYİĞİT G., HÜR MÜZ P., YALÇIN Ş., CENGİZ M.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.4, pp.233-238, 2012 (SCI-Expanded)
- CIX. **Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group**
ÜRÜN Y., Utkan G., YALÇIN Ş., COŞKUN H. Ş., Kocer M., Ozdemir N. Y., Kaplan M. A., Arslan U. Y., ÖZDEMİR F., ÖZTUNA D., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.8, pp.4129-4131, 2012 (SCI-Expanded)
- CX. **Evaluation of Dietary and Life-Style Habits of Patients with Gastric Cancer: A Case-Control Study in Turkey**
YASSIBAŞ E., Arslan P., YALÇIN Ş.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.5, pp.2291-2297, 2012 (SCI-Expanded)
- CXI. **Impact of Adjuvant Chemoradiotherapy for Rectal Cancer on the Long-Term Quality of Life and Late Side Effects: A Multicentric Clinical Evaluation by the Turkish Oncology Group**
Kilic D., Yalman D., Aksu G., ATASOY B. M., Igdem S., DİNÇBAŞ H. F., YALÇIN Ş.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.11, pp.5741-5746, 2012 (SCI-Expanded)
- CXII. **Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey**
Dogan E., YALÇIN Ş., Koca D., Olmez A.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.6, pp.2985-2990, 2012 (SCI-Expanded)
- CXIII. **Nilotinib in Advanced Gastrointestinal Stromal Tumors after Imatinib and Sunitinib Therapy**
Dizdar O., YALÇIN Ş.

- HEPATO-GASTROENTEROLOGY, vol.58, no.112, pp.2012-2014, 2011 (SCI-Expanded)
- CXIV. **Breast milk lead and cadmium levels from suburban areas of Ankara**
Orun E, YALÇIN Ş., Aykut O., Orhan G., Morgil G. K., YURDAKÖK K., Uzun R.
SCIENCE OF THE TOTAL ENVIRONMENT, vol.409, no.13, pp.2467-2472, 2011 (SCI-Expanded)
- CXV. **Nilotinib is Effective in Imatinib and Sunitinib Resistant GIST: A Case Report**
DİZDAR Ö., YALÇIN Ş.
HEPATO-GASTROENTEROLOGY, vol.58, no.107, pp.859-860, 2011 (SCI-Expanded)
- CXVI. **Evaluation of sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma.**
Ricke J., Schuette K., Graziadei I. W., Jakob A., Verslype C., Sangro B., Walecki J., Kluempfen H. J., Peynircioglu B., Yalcin S., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CXVII. **Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial**
Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CXVIII. **The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study.**
Turhal N. S., Kilickap S., Yalcin S., Sezgin C., Yamac D., Akbulut H., Ozyilkan O., Ozdemir F., Cabuk D., Sevinc A.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CXIX. **Advances in the systemic treatment of pancreatic neuroendocrine tumors**
Yalcin S.
CANCER TREATMENT REVIEWS, vol.37, no.2, pp.127-132, 2011 (SCI-Expanded)
- CXX. **A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer**
Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.4, 2011 (SCI-Expanded)
- CXXI. **Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature**
ARSLAN Ç., KILIÇKAP S., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.22, no.1, pp.73-76, 2011 (SCI-Expanded)
- CXXII. **Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study-A Turkish Oncology Group trial**
Aykan N., Demir G., Disci R., Yalcin S., Turhal N. S., Ozdogan M., Ozkan M., Yaren A., Camel C., Akbulut H.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.4, 2011 (SCI-Expanded)
- CXXIII. **Hepatitis A seroprevalence among infants aged 12 months in Ankara**
Ince O. T., YALÇIN Ş., YURDAKÖK K., ÖZMERT E. N.
TURKISH JOURNAL OF PEDIATRICS, vol.53, no.1, pp.114-116, 2011 (SCI-Expanded)
- CXXIV. **The First Line Systemic Chemotherapy in Metastatic Gastric Carcinoma: A Comparison of Docetaxel, Cisplatin and Fluorouracil (DCF) Versus Cisplatin and Fluorouracil (CF); Versus Epirubicin, Cisplatin and Fluorouracil (ECF) Regimens in Clinical Setting**
KILIÇKAP S., YALÇIN Ş., ATEŞ Ö., Tekuzman G.
HEPATO-GASTROENTEROLOGY, vol.58, no.105, pp.208-212, 2011 (SCI-Expanded)
- CXXV. **Zinc supplementation and TNF-alpha levels in vaccinated cardiac patients**
YALÇIN Ş., Engur-Karasimav D., ALEHAN D., YURDAKÖK K., Ozkutlu S., COŞKUN T.
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, vol.25, no.2, pp.85-90, 2011 (SCI-Expanded)
- CXXVI. **Why are they having infant colic? A nested case-control study**
YALÇIN Ş., ORUN E., MUTLU B., MADENDAG Y., Sinici İ., DURSUN A., ÖZKARA H. A., USTUNYURT Z., KUTLUK S., Yurdakok K.

- PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, vol.24, no.6, pp.584-596, 2010 (SCI-Expanded)
- CXXVII. **Sensitivity and specificity of bloody diarrhea in shigella gastroenteritis**
ÖZMERT E. N., ORUN E., ŞENGELEN M., YALÇIN Ş., YURDAKÖK K., GÜR D.
TURKISH JOURNAL OF PEDIATRICS, vol.52, no.5, pp.488-490, 2010 (SCI-Expanded)
- CXXVIII. **Serological response to influenza vaccine after hematopoietic stem cell transplantation**
YALÇIN Ş., Kondolot M., Albayrak N., Altas A. B., Karacan Y., Kuskonmaz B. B., AKSU S., Cetin M., GÖKER H., YURDAKÖK K., et al.
ANNALS OF HEMATOLOGY, vol.89, no.9, pp.913-918, 2010 (SCI-Expanded)
- CXXIX. **Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia**
Aytac Ş. S., YALÇIN Ş., Cetin M., Yetgin S., GÜMRÜK F., Tuncer M., YURDAKÖK K., Gurgey A.
Pediatric Hematology and Oncology, vol.27, no.5, pp.333-343, 2010 (SCI-Expanded)
- CXXX. **Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial**
Ocvirk J., Brodowicz T., Wrba F., Ciuleanu T. E., Kurteva G., Beslija S., Koza I., Zsuzsanna Papai Z. P., Messinger D., Yilmaz U., et al.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.16, no.25, pp.3133-3143, 2010 (SCI-Expanded)
- CXXXI. **FEEDING PRACTICES OF 12-23 MONTHS AGED CHILDREN IN TURKEY**
Koksal E., YALÇIN Ş., Tezel B., Pekcan G., Sahin S., Ozbas S., YURDAKÖK K., Tunc B., Altinsu T., Kose M., et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol.50, 2010 (SCI-Expanded)
- CXXXII. **Registry of Gastric Cancer Treatment Evaluation (REGATE): Variation in nonsurgical therapies**
Yalcin S., Serraiwa M., Arbeloa P., Kang W., Bang Y., Gumus M., Wu C., Roth A., Ecstein-Fraisse E. B., Ter-Ovanesov M.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXXXIII. **Registry of Gastric Cancer Treatment Evaluation (REGATE): Staging and diagnosis of 10,124 patients (pts)**
Wu C., Soloviev V., Semkina E., Ter-Ovanesov M., Babu K. G., Vila A., Yalcin S., Roth A., Ecstein-Fraisse E. B., Bang Y.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXXXIV. **Registry of Gastric Cancer Treatment Evaluation (REGATE): Regional differences in surgical approaches**
Ter-Ovanesov M., Kulig J., Munasyrov F., Bang Y., Yalcin S., Roth A., Zalberg J. R., Ecstein-Fraisse E. B., Wu C.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXXXV. **The awareness and knowledge levels of colorectal cancer (CRC) patients and their first-degree relatives (FDR) for CRC screening**
Arslan C., Kilickap S., Rama D., Yalcin S.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXXXVI. **Registry of Gastric Cancer Treatment Evaluation (REGATE): Geographic analysis of baseline characteristics of 10,124 patients (pts)**
Zalberg J. R., Mohandas K. M., Kang Y., Bang Y., Ter-Ovanesov M., Ben Ahmed S., Wu C., Roth A., Ecstein-Fraisse E. B., Yalcin S.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXXXVII. **The Factors that have a Role in Variability for Temperature**
YALÇIN Ş., Aydemir O., Erkul E., KARABULUT E., Akca T.
JOURNAL OF TROPICAL PEDIATRICS, vol.56, no.1, pp.53-59, 2010 (SCI-Expanded)
- CXXXVIII. **Factors associated with breastfeeding initiation time in a Baby-Friendly Hospital**
Orun E., YALÇIN Ş., Madendag Y., Ustunyurt-Eras Z., Kutluk S., YURDAKÖK K.
TURKISH JOURNAL OF PEDIATRICS, vol.52, no.1, pp.10-16, 2010 (SCI-Expanded)
- CXXXIX. **Maternal and environmental determinants of breast-milk mercury concentrations**
YALÇIN Ş., YURDAKÖK K., Yalcin S. S., Engur-Karasimav D., COŞKUN T.
TURKISH JOURNAL OF PEDIATRICS, vol.52, no.1, pp.1-9, 2010 (SCI-Expanded)
- CXL. **Feeding on one side or both sides in a breast-feeding session**
KONDOLOT M., YALÇIN Ş., YURDAKÖK K.
PEDIATRICS INTERNATIONAL, vol.51, no.6, pp.817-820, 2009 (SCI-Expanded)

- CXLI. **Seasonal and gender differences in hemoglobin value in infants at 5-7 months of age**
YALÇIN Ş., Dut R., YURDAKÖK K., Ozmert E.
TURKISH JOURNAL OF PEDIATRICS, vol.51, no.6, pp.572-577, 2009 (SCI-Expanded)
- CXLII. **Effects of early feed restriction on live performance, carcass characteristics, meat and liver composition, some blood parameters, heterophil-lymphocyte ratio, antibody production and tonic immobility duration**
Onbasilar E. E., Yalcin S., Torlak E., Ozdemir P.
TROPICAL ANIMAL HEALTH AND PRODUCTION, vol.41, no.7, pp.1513-1519, 2009 (SCI-Expanded)
- CXLIII. **Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial**
Curran D., Pozzo C., Zaluski J., Dank M., Barone C., Valvere V., YALÇIN Ş., Peschel C., Wenczl M., GÖKER E., et al.
QUALITY OF LIFE RESEARCH, vol.18, no.7, pp.853-861, 2009 (SCI-Expanded)
- CXLIV. **Changes in serum leptin concentrations in rats according to malnutrition models and effects of carnitine supplementation on catch-up growth**
ONBAŞILAR İ., YALÇIN Ş.
REVUE DE MEDECINE VETERINAIRE, vol.160, no.7, pp.362-369, 2009 (SCI-Expanded)
- CXLV. **Comparison of acute bloody and watery diarrhea: a case control study**
Kuskonmaz B. B., YURDAKÖK K., YALÇIN Ş., Ozmert E.
TURKISH JOURNAL OF PEDIATRICS, vol.51, no.2, pp.133-140, 2009 (SCI-Expanded)
- CXLVI. **NFKB1-94 Insertion/Deletion ATG Polymorphism in Gastroenteropancreatic Neuroendocrine Tumors**
Burnik F. S., YALÇIN Ş.
CHEMOTHERAPY, vol.55, no.5, pp.381-385, 2009 (SCI-Expanded)
- CXLVII. **Nutrition and Gastric Cancer in Turkey**
YALÇIN Ş.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.61, no.6, pp.900-902, 2009 (SCI-Expanded)
- CXLVIII. **Effects of the usage of dried brewing yeast in the diets on the performance, egg traits and blood parameters in quails**
Yalcin S., Erol H., Oezsoy B., Onbasilar I., Yalcin S.
ANIMAL, vol.2, no.12, pp.1780-1785, 2008 (SCI-Expanded)
- CXLIX. **Clinical presentation and management of Gastroesophageal reflux disease in a referral center in Turkey**
YALÇIN Ş., ÇİFTÇİ A. Ö., Senocak M. E., TANYEL F. C.
EUROPEAN JOURNAL OF PEDIATRIC SURGERY, vol.18, no.3, pp.180-184, 2008 (SCI-Expanded)
- CL. **Prophylactic use of acetaminophen in children vaccinated with diphtheria-tetanus-pertussis**
YALÇIN Ş., Gumus A., YURDAKÖK K.
WORLD JOURNAL OF PEDIATRICS, vol.4, no.2, pp.127-129, 2008 (SCI-Expanded)
- CLI. **Validity of using pallor to detect children with mild anemia**
YURDAKÖK K., Guner S. N., YALÇIN Ş.
PEDIATRICS INTERNATIONAL, vol.50, no.2, pp.232-234, 2008 (SCI-Expanded)
- CLII. **Sparing of previously irradiated skin from eriotinib-induced acneiform rash**
YALÇIN Ş., Dizdar O., Yalcin B., Goekoez Ö.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol.58, no.1, pp.178-179, 2008 (SCI-Expanded)
- CLIII. **Seasonal and gender differences in the prevalence of infant anemia**
YALÇIN Ş., Dut R., YURDAKÖK K., Ozmert E.
PEDIATRICS, vol.121, 2008 (SCI-Expanded)
- CLIV. **Current medical treatment of pancreatic neuroendocrine tumors**
Yalcin S., Oyan B., Bayraktar Y.
HEPATO-GASTROENTEROLOGY, vol.54, no.73, pp.278-284, 2007 (SCI-Expanded)
- CLV. **Lightning: A risk factor for squamous cell carcinoma of the skin**

- Purnak T, Kilickap S, Aksoy S, Yalcin S.
CLINICAL ONCOLOGY, vol.18, no.8, pp.636, 2006 (SCI-Expanded)
- CLVI. **Cutaneous metastases of signet cell carcinoma of the rectum without accompanying visceral involvement**
Kilickap S, Aksoy S, Dincer M, Saglam E. A., Yalcin S.
SOUTHERN MEDICAL JOURNAL, vol.99, no.10, pp.1137-1139, 2006 (SCI-Expanded)
- CLVII. **Orbital metastasis from adenocarcinoma of the colon**
Dizdar O, Aksoy S, Kilickap S, Yalcin S.
SOUTHERN MEDICAL JOURNAL, vol.98, no.8, pp.846-847, 2005 (SCI-Expanded)
- CLVIII. **Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient**
Aksoy S, KARACA B., DİNÇER M., Yalcin S.
ANNALS OF PHARMACOTHERAPY, vol.39, no.3, pp.573-574, 2005 (SCI-Expanded)
- CLIX. **Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: Results of single-center study of 45 patients**
Altundag O, Gullu I, Altundag K, Yalcin S, Ozyar E, Cengiz M, Akyol F, Yucel T, Hosal S, Sozeri B.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, vol.27, no.1, pp.15-21, 2005 (SCI-Expanded)
- CLX. **Diagnosis and management of cholangiocarcinomas: A comprehensive review**
Yalcin S.
HEPATO-GASTROENTEROLOGY, vol.51, no.55, pp.43-50, 2004 (SCI-Expanded)
- CLXI. **Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy**
Altundag K, Aksoy S, Gullu I, Altundag O, Ozyar E, Yalcin S, Cengiz M, Akyol F.
MEDICAL ONCOLOGY, vol.21, no.3, pp.211-215, 2004 (SCI-Expanded)
- CLXII. **Prognostic factors and outcome in 306 patients with diffuse large B-cell lymphoma (DLBCL)**
OYAN ULUÇ B., Tekuzman G., BARIŞTA İ., Ozisik Y., kars A., Turker A., YALÇIN Ş., Guler N., Koc Y., KANSU E.
ANNALS OF ONCOLOGY, vol.15, pp.153, 2004 (SCI-Expanded)
- CLXIII. **Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer**
Yalcin S, Oksuzoglu B, Tekuzman G, Engin H, Celik I, Turker A, Barista I, Gullu I, Guler N, Altundag K, et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.33, no.11, pp.580-583, 2003 (SCI-Expanded)
- CLXIV. **Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: Efficacy and prognostic factors**
Karaoglu A, Yalcin S, Tekuzman G, Kars A, Celik I, Guler N, Ozisik Y, Turker A, Barista I, Gullu I.
TUMORI, vol.89, no.2, pp.141-145, 2003 (SCI-Expanded)
- CLXV. **Reactivation of hepatitis B virus infection in pancreatic cancer: a case report**
Oksuzoglu B, Kilickap S, Yalcin S.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.32, no.12, pp.543-545, 2002 (SCI-Expanded)
- CLXVI. **Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: Results of a single-center study of 32 patients**
Ozturk M, Barista I, Altundag M, Turker A, Yalcin S, Celik I, Gullu İ. H., Guler N, Ozisik Y, Kars A, et al.
CHEMOTHERAPY, vol.48, no.5, pp.252-258, 2002 (SCI-Expanded)
- CLXVII. **Role of self-expandable metal stents (SEMS) in colorectal malignancy**
Yalcin S, Singh S, Gagneja H, Kalha I, Patel M, Lenzi R, Kaw M.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.97, no.9, 2002 (SCI-Expanded)
- CLXVIII. **Abdominal pain in a diabetic myeloma patient with cirrhosis**
GÖNEN C., Oksuzoglu B, Yalcin S.
POSTGRADUATE MEDICAL JOURNAL, vol.78, no.920, pp.375-376, 2002 (SCI-Expanded)
- CLXIX. **Squamous cell carcinoma of the tongue in a patient with Fanconi's anemia: a case report and review**

of the literature

Oksuzoglu B., Yalcin S.

ANNALS OF HEMATOLOGY, vol.81, no.5, pp.294-298, 2002 (SCI-Expanded)

- CLXX. **Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy**
Lenzi R., Yalcin S., Evans D., Abbruzzese J.
CANCER INVESTIGATION, vol.20, no.4, pp.464-472, 2002 (SCI-Expanded)
- CLXXI. **The effects of tannic acid and lignosulfonate treatments of sunflower seed meal on the digestibility and rumen degradability characteristics of some nutrients in rams**
Yalcin S., Sehu A., Guclu B., Onbasilar I., Sarifakiogullari K.
TURKISH JOURNAL OF VETERINARY & ANIMAL SCIENCES, vol.26, no.4, pp.805-813, 2002 (SCI-Expanded)
- CLXXII. **Generalized lymphadenopathy - A rare presentation of disseminated prostate cancer**
Oyan B., Engin H., Yalcin S.
MEDICAL ONCOLOGY, vol.19, no.3, pp.177-179, 2002 (SCI-Expanded)
- CLXXIII. **Leptomeningeal infiltration of malignant mesothelioma**
Oksuzoglu B., Yalcin S., Erman M., Dagdelen S.
MEDICAL ONCOLOGY, vol.19, no.3, pp.167-169, 2002 (SCI-Expanded)
- CLXXIV. **Syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with prostatic carcinoma**
Yalcin S., Erman M., Tekuzman G., Ruacan S.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.23, no.4, pp.384-385, 2000 (SCI-Expanded)
- CLXXV. **Primary low grade B-cell lymphoma of the dura in an immunocompetent patient**
Altundag M., Ozisik Y., Yalcin S., Akyol F., Uner A.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.19, no.2, pp.249-251, 2000 (SCI-Expanded)
- CLXXVI. **Management of patients with cancer of unknown primary site - The Hainsworth/Greco article reviewed**
Lenzi R., Yalcin S.
ONCOLOGY-NEW YORK, vol.14, no.4, pp.576-578, 2000 (SCI-Expanded)
- CLXXVII. **Organ preservation by induction chemotherapy plus radiotherapy in locally advanced larynx and hypopharynx cancers: Preliminary results.**
Gullu Y., Altundag M., Yalcin S., Altundag O., Tekuzman G., Ozyar E., Akyol F., Yucel T., Hosal S., Kaya S.
ANNALS OF ONCOLOGY, vol.11, pp.94, 2000 (SCI-Expanded)
- CLXXVIII. **Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy**
Barista I., Tekuzman G., Yalcin S., Gullu I., Guler N., Ozisik Y., Kars A., Celik I., Turker A., Altundag K., et al.
JOURNAL OF SURGICAL ONCOLOGY, vol.73, no.1, pp.12-16, 2000 (SCI-Expanded)
- CLXXIX. **COMPUTERIZED ANALYSIS OF ANTEPARTUM FETAL HEART-RATE TRACINGS IN NORMAL PREGNANCIES (VERSION 88/2.29)**
BEKSAC M., KARAKAS U., YALCIN S., OZDEMIR K., SANLITURK E.
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol.37, no.2, pp.121-132, 1990 (SCI-Expanded)
- CLXXX. **DEVELOPMENT AND APPLICATION OF A SIMPLE EXPERT SYSTEM FOR THE INTERPRETATION OF THE ANTEPARTUM FETAL HEART-RATE TRACINGS (VERSION 88/2.29)**
BEKSAC M., OZDEMIR K., KARAKAS U., YALCIN S., KARAAGAOGLU E.
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol.37, no.2, pp.133-141, 1990 (SCI-Expanded)

- I. **Assessment of the Clinicopathologic Characteristics and Survival Rates of Colorectal Cancer Among Syrian Refugees and Turkish Population in Gaziantep Province**
Karan C., Okten I. N., KESEN O., Celikyurek A., Teker F., YALÇIN Ş.
JCO GLOBAL ONCOLOGY, vol.10, 2024 (ESCI)
- II. **Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab**
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., AKSOY S., ERMAN M., YALÇIN Ş., Kilickap S.
Journal of Immunotherapy and Precision Oncology, vol.6, no.4, pp.170-176, 2023 (Scopus)
- III. **Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer**
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., AKYILDIZ A., YILMAZ F., YAŞAR S., Evlendi Y., et al.
Journal of Oncological Science, vol.9, no.1, pp.33-37, 2023 (Scopus)
- IV. **Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience**
Erol C., Bardakçı M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., Aykan M. B., Ak R., Ateş Ö., ŞENER DEDE D., et al.
Journal of Oncological Science, vol.9, no.2, pp.72-78, 2023 (Scopus)
- V. **Long-term results of radiofrequency and microwave ablation of colorectal cancer liver metastasis**
ERDEMİR A. G., KARAHAN S., ÜNAL E., ÇİFTÇİ T. T., AKINCI D., YALÇIN Ş., AKHAN O.
International Journal of Gastrointestinal Intervention, vol.12, no.3, pp.130-139, 2023 (ESCI)
- VI. **Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review**
YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., AKIN S., YALÇIN Ş., BARIŞTA İ.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, vol.15, no.4, pp.307-310, 2022 (ESCI)
- VII. **Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)
- VIII. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.
Journal of Oncological Science, vol.8, no.3, pp.143-147, 2022 (Scopus)
- IX. **Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department**
ÖCAL O., Eldem G., KARAGÖZ A. H., KILIÇKAP S., YALÇIN Ş., BALKANCI F., PEYNİRCİOĞLU B.
CUREUS, vol.13, no.9, 2021 (ESCI)
- X. **Artificial intelligence method to predict overall survival of hepatocellular carcinoma**
ŞİMŞEK C., GÜVEN D. C., Sahin T. K., TEKİN İ. E., Sahan O., BALABAN H. Y., YALÇIN Ş.
Hepatology Forum, vol.2, no.2, pp.64-68, 2021 (Scopus)
- XI. **Stereotactic ablative radiotherapy for bone metastasis of gastrointestinal stromal tumor: Case report and review of the literature**
YILMAZ M. T., GÜLTEKİN M., YALÇIN Ş., TUNCEL M., Gedikoglu G., YILDIZ F., CENGİZ M.
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, vol.25, no.3, pp.331-335, 2020 (ESCI)
- XII. **Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience**
YALÇIN Ş., HÜRMÜZ P., McQuinn L., Naing A.
JOURNAL OF GLOBAL ONCOLOGY, vol.4, 2017 (ESCI)
- XIII. **Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival**

Turkoz F. P., Solak M., KILIÇKAP S., Ulas A., Esbah O., Oksuzoglu B., YALÇIN Ş.

JOURNAL OF GASTRIC CANCER, vol.14, no.3, pp.164-172, 2014 (ESCI)

XIV. Current and future systemic treatment options in metastatic pancreatic cancer

Arslan C., YALÇIN Ş.

JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.5, no.4, pp.280-295, 2014 (ESCI)

XV. Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: impact of patient education before treatment initiation

POLAT Ü., Arpacı A., DEMİR S., Erdal S., YALÇIN Ş.

JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.5, no.4, pp.270-275, 2014 (ESCI)

Books & Book Chapters

I. Hypoglycemia and Hyperglycemia in Critically Ill Cancer Patients

OĞUZ S. H., ÜNLÜTÜRK U., LAÇİN Ş., GÜRLEK Ö. A., YALÇIN Ş.

in: Oncologic Critical Care, Nates J., Price K, Editor, springer, pp.1079-1091, 2020

II. treatment of rectal cancer

ARTAÇ M., elrayes b. f., YALÇIN Ş., philip p. a.

in: textbook of gastrointestinal cancer patients, Suayib Yalcin, Philip a. Philip, Editor, springer, pp.161-174, 2019

III. Nutrition and Cachexia in Gastrointestinal Cancer Patients

HALİL M. G., Kuyumcu M. E., DİZDAR Ö., ÜLGER Z., YALÇIN Ş.

in: Textbook of Gastrointestinal Oncology, Yalçın Şuayib, Philip A. Philip, Editor, Springer, pp.379-394, 2019

IV. esophageal and gastroesophageal junction tumors

YALÇIN Ş., DİZDAR Ö., KILIÇKAP S., cilbir e., philip p. a.

in: textbook of gastrointestinal oncology, Suayib Yalcin, Philip a. Philip, Editor, springer, pp.55-72, 2019

V. Mide kanserinde tanı ve patoloji

YALÇIN Ş., ÇİÇİN İ., AYKAN N. F., MANDEL N. K.

in: İleri evre mide kanserinde tedavi yaklaşımları, Yalçın Şuayib, Öksüzoğlu Berna, Editor, Ortadoğu reklam tanıtım yayıncılık A.Ş, pp.12-18, 2018

VI. Mide kanseri insidansı ve epidemiyolojisi

YALÇIN Ş., AYKAN N. F., ÇİÇİN İ., MANDEL N. K.

in: İLERİ EVRE MİDE KANSERİNDE TEDAVİ YAKLAŞIMLARI, Yalçın Şuayib, Öksüzoğlu Berna, Editor, ORTADOĞU REKLAM TANITIM YAYINCILIK AŞ, pp.1-11, 2018

VII. Evreleme ve Preoperatif değerlendirme

YALÇIN Ş., ÇİÇİN İ., AYKAN N. F., MANDEL N. K.

in: İleri evre mide kanserinde tedavi yaklaşımları, Yalçın Şuayib, Öksüzoğlu Berna, Editor, Ortadoğu reklam tanıtım yayıncılık A.Ş, pp.19-24, 2018

Refereed Congress / Symposium Publications in Proceedings

I. Prognostic Impact of Circulating Angiogenic Factors in 90Y Microsphere Treatment

MAVİ M. E., VOLKAN SALANCI B., LAY İ., ELDEM F. G., PEYNİRCIOĞLU B., YALÇIN Ş., UĞUR Ö., BOZKURT M. F.

55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON), Jodhpur, India, 16 - 19 November 2023

II. the role of neoadjuvant radiotherapy in rectal cancer: hacettepe university experience

HÜR MÜZ P., TİL Kİ B., YILDIZ F., ÖZYİĞİT G., EROL T., KONAN A., ZORLU A. F., YALÇIN Ş., AKYOL H. F.

9th international gastrointestinal cancer conference, 6 - 08 December 2019

III. prognostic significance of ıgf-1 in hepatocellular cancer patients turkish validation study

LAÇİN Ş., Karakas Y., Abdel Wahab R., HASSAN M., Lianchun X., KASEB A., YALÇIN Ş.

9 th international gastrointestinal cancer conference, 6 - 08 December 2019

IV. Definitive Chemoradiotherapy in Esophageal Squamous Cell Cancer: A Single Center Experience

YILMAZ M. T., HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F., AKYOL H. F., YALÇIN Ş., ÖZYİĞİT G.

9th International Gastrointestinal Cancer Conference, İstanbul, Turkey, 6 - 08 December 2019

- V. **importance of serum vegfa level in hepatocellular cancer patients, its relationship with clinicopathologic parameters**
LAÇİN Ş., Karakas Y., YALÇIN Ş.
9 th international gastrointestinal cancer conference, 6 - 08 December 2019
- VI. **non-operative management of rectal cancer: hacettepe university experience**
TİLKİ B., HÜRMÜZ P., CENGİZ M., ZORLU A. F., ÖZYİĞİT G., YILDIZ F., YALÇIN Ş., AKYOL H. F.
9th international gastrointestinal cancer conference, 6 - 08 December 2019
- VII. **DEFİNİTİVE CHEMORADİOTHERAPY İN ESOPHAGEAL SQUAMOUS CELL CANCER A SINGLE CENTER EXPERİENCE**
HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F., AKYOL H. F., YALÇIN Ş., ÖZYİĞİT G.
9 th international gastrointestinal cancer conference, 6 - 08 December 2019
- VIII. **outcomes of patients with resected pancreatic ductal adenocarcinoma**
ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., KILIÇKAP S., YALÇIN Ş., DİZDAR Ö.
9th international gastrointestinal cancer conference, 6 - 08 December 2019
- IX. **A Single Center Experience of Neoadjuvant Radiotherapy in Rectal Cancer**
HÜRMÜZ P., TİLKİ B., CENGİZ M., YILDIZ F., ÖZYİĞİT G., EROL T., KONAN A., ZORLU A. F., YALÇIN Ş., AKYOL H. F.
6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 November - 01 December 2019, vol.5
- X. **The Role of Radiotherapy /- Chemotherapy in the treatment of Rectal Cancer: Single Center Experience**
TİLKİ B., HÜRMÜZ P., CENGİZ M., YILDIZ F., ZORLU A. F., ÖZYİĞİT G., YALÇIN Ş., AKYOL H. F.
6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 November - 01 December 2019, vol.5
- XI. **Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).**
Alsina M., Taberero J., Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., Ghidini M., Faustino C., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XII. **Clinical features and prognosis of patients with liposarcoma: Single-center experience.**
Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., Kilickap S., Kars A., Turker A., Yalcin S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XIII. **COMBINATION OF OxALIPLATIN, CAPECITABINE, trastuzumab and chemotherapy INPATIENTS WITH GASTRIC CANCER**
ABALI H., YALÇIN Ş., ÖNAL H. C., DANE F., ÇAKMAK ÖKSÜZOĞLU Ö. B., ÖZDEMİR N., MERTSOYLU H., ARTAÇ M., camcı c., başol f., et al.
8 th INTERNATIONALGASTROINTESTINALCANCER CONFERENCE, 7 - 09 December 2018
- XIV. **Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi**
GÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., YILMAZ E., KARAKOÇ D., HAMALOĞLU E., YALÇIN Ş., et al.
2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018
- XV. **A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).**
Abali H., Yalcin S., Onal C., Dane F., Oksuzoglu B., Ozdemir N., Mertsoylu H., Artac M., Camci C., Karabulut B., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36
- XVI. **Economic Burden of Gastric Cancer in Turkey**
BİLİCİ A., GÜMÜŞ M., MALHAN B. S., Öksüz E., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN Ş.

ISPOR 20th Annual European Congress, 4 - 08 November 2017

- XVII. **Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.**
Escobar N. E. I., Luaces P. L., Valdes L. S., Silva C. V., Ramos T. C., Strumberg D., Schultheis B., Ebert M. P., Kerkhoff A., Hofheinz R., et al.
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35
- XVIII. **Beyin Tumorlerinde Serum Peptidomik Analiz**
PINAR A., KUTLUK M. T., Mut A. M., KARAHAN S., AKALAN N., YALÇIN Ş., HASÇELİK A. G.
22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017
- XIX. **FREQUENCY OF CHEMOTHERAPY INDUCED AMENORRHEA IN WOMEN WITH COLORECTALCANCER**
ŞAHİN T., DİZDAR Ö., ÖZDEMİR N., ZENGİN N., ATEŞ Ö., ÇAKMAK ÖKSÜZOĞLU Ö. B., ŞENDUR M. A. N., BİLGİN B., Bozkurt U. B., demir m., et al.
International Congress on Oncological Sciences, 27 September - 01 October 2017
- XX. **A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).**
Abali H., Yalcin S., Onal H. C., Dane F., Oksuzoglu B., Ozdemir N., Mertsoylu H., Artac M., Camci C., Karabulut B., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 21 - 23 January 2016, vol.34
- XXI. **Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factors**
Goker H., Gunes G., Demiroglu H., Malkan Ü. Y., Haznedaroglu I., Sayinalp N., Etgul S., Eliacik E., Aslan T., Isik A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXII. **Signet ring cell carcinoma of breast: Single center experience.**
AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., Altundag K.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXIII. **frequency of c Met HGF and HER 2 expression and evaluation of their association with clinicopathological and prognostic factors in gastric cancer**
YALÇIN Ş., yetkin y., SÖKMENSÜER C.
gastrointestinal cancers symposium 2015, 15 - 17 January 2015
- XXIV. **Frequency of c-Met, HGF, and HER-2 expression and evaluation of their association with clinicopathologic and prognostic factors in gastric cancer.**
YALÇIN Ş., Yildiz Y., SÖKMENSÜER C.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 15 - 17 January 2015, vol.33
- XXV. **Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.**
Yetisyigit T., Babacan N., Urun Y., Seber S., Arpacı E., Clhan S., Ylirim N., Oksuzoglu O. B., Aksoy S., Budakoglu B., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXVI. **Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (SORAMIC).**
Ricke J., Schutte K., Rosmorduc O., Peck-Radosavljevic M., Verslype C., Sangro B., Waleckl J., Klumpen H., Peynircioglu B., Yalcin S., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXVII. **Evaluation of the frequency of c-Met and HER2 expressions in gastric carcinoma and their**

association with clinicopathologic factors

YALÇIN Ş., Yildiz Y., SÖKMENSÜER C.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 16 - 18 January 2014, vol.32

- XXVIII. **Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results**
Ravaud A., Barrios C. H., Alekseev B. Y., Tay M. H., Agarwala S. S., Yalcin S., Lin C., Shkolnik M., Matveev V., Anak O., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXIX. **Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)**
Strumberg D., Schultheis B., Ebert M. P., Kerkhoff A., Hofheinz R. D., Behringer D. M., Schmidt W. E., Goker E., De Dosso S., Kneba M., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXX. **The impact of adjuvant delayed radiotherapy (RT) on survival in patients with resected periampullary adenocarcinomas.**
Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXXI. **Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study**
Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XXXII. **Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.**
Yalcin S., Buyukberber S., Yilmaz U., Lee P., Srimuninnimit V., Lin P., Elserafy M. M., Manieh M., Sunpaweravong P., Istomin Y., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XXXIII. **Post-Progression Therapies in Patients with Advanced Neuroendocrine Tumors (NET): Analysis From the RADIANT-2 Trial**
Hobday T., Becerra C., YALÇIN Ş., Panneerselvam A., Saletan S., Hainsworth J.
76th Annual Scientific Meeting of the American-College-of-Gastroenterology, Washington, Kiribati, 28 October - 02 November 2011, vol.106
- XXXIV. **POST-STUDY TREATMENT OPTIONS ARE LIMITED IN PATIENTS WITH ADVANCED NET: ANALYSIS OF POST-PROGRESSION THERAPIES FROM THE RADIANT-2 TRIAL**
Peeters M., Becerra C., Panneerselvam A., Saletan S., YALÇIN Ş.
European-Society-for-Medical-Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 22 - 25 June 2011, vol.22
- XXXV. **Serological response to influenza vaccine haematopoietic stem cell transplantation patients**
YALÇIN Ş., Kondolot M., Albayrak N., Altas B., Karacan Y., KUŞKONMAZ B. B., AKSU S., ÇETİN M., GÖKER H., YURDAKÖK K., et al.
36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Vienna, Austria, 21 - 24 March 2010, vol.45
- XXXVI. **REGATE: What happens to gastric cancer treatment in the real world?**
Ter-Ovanesov M., Bang Y., Wu C., Yalcin S., Roth A., Zalcborg J., Soloviev V., Oliveros R., Yankin A., Narvaez C.

Satellite Symposium on New Horizons for Gastric Cancer held in conjunction with the 8th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 29 June 2006, vol.17, pp.31

- XXXVII. **Clinical profile of gastric cancer in Turkey: Factors effecting disease free survival and relapse (Turkish Oncology Group Study)**
Demir G., Zengin N., Yildiz O., Ozdamar S., Aykan F., Er O., Ilhan M., Turhal S., Yilmaz U., Yalcin S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.324-325
- XXXVIII. **Bone marrow metastasis in solid tumors: Clinical evaluation of 64 cases.**
Kilickap S., Erman M., Dincer M., Aksoy S., Harputluoglu H., Yalcin S.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XXXIX. **Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases**
Oyan B., Tekuzman G., Barista I., Kars A., Turker A., Ozisik Y., Guler N., Baltali E., Yalcin S., Gullu I.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XL. **Ifosfamide-doxorubicin combination in patients with locally recurrent or metastatic nasopharyngeal carcinoma pretreated with cisplatin based chemotherapy: Retrospective analysis of 21 patients.**
Altundag K., Aksoy S., Gullu I., Altundag O., Ozyar E., Yalcin S., Cengiz M., Akyol F.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

Supported Projects

YALÇIN Ş., Project Supported by Higher Education Institutions, Kanser Hastalarında Tamamlayıcı Tıp Kullanımı Hacettepe Üniversitesi Deneyimi (Prevalence of Complementary Medicine Use in Cancer Patients Hacettepe University Experience), 2017 - 2020

Metrics

Publication: 247

Citation (WoS): 1223

Citation (Scopus): 462

H-Index (WoS): 19

H-Index (Scopus): 12

Non Academic Experience

Türk Kanser Araştırma ve Savaş Kurumu Derneği

HACETTEPE

Türk Tıbbi Onkoloji Derneği

Texas University MD Anderson Cancer Center